Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Baylor College of Medicine
Regeneron Pharmaceuticals
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
University of Pennsylvania
Fate Therapeutics
UNC Lineberger Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Medical College of Wisconsin
City of Hope Medical Center
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Genmab
Stanford University
Daiichi Sankyo
Cullinan Therapeutics Inc.